Icade Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Die Gewinne von Icade sind mit einer durchschnittlichen Jahresrate von -31.4% zurückgegangen, während die Gewinne der Branche REITs um 20.6% pro Jahr zurückgingen. Die Umsätze sind zurückgegangen mit einer durchschnittlichen Jahresrate von 2.9%.
Wichtige Informationen
-31.35%
Wachstumsrate der Gewinne
-31.46%
EPS-Wachstumsrate
| REITs Wachstum der Industrie | 12.57% |
| Wachstumsrate der Einnahmen | -2.86% |
| Eigenkapitalrendite | -3.23% |
| Netto-Marge | -9.20% |
| Nächste Ertragsaktualisierung | 21 Jul 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
ICAD: Cautious Outlook And Special Meeting Timing Will Shape Balanced Future
Analysts have nudged their fair value estimate for Icade from €21.31 to €21.67, reflecting a slightly higher €22 price target and a view that the stock now presents more limited downside at current levels. What’s in the News for Icade Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026.
ICAD: Limited Downside View Will Still Pressure Shares Going Forward
Analysts have raised their fair value estimate for Icade from €16.30 to €17.00, citing a higher Street price target of €22 and the view that downside risk at current levels now appears more limited. What's in the News Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026, at the Coeur Defense building, Tour B Espace Comet, 24th floor, 100 Esplanade du General de Gaulle, Paris La Defense Cedex, France.ICAD: Slower Healthcare Exit And Paused Special Payouts Will Shape Balanced Outlook
Analysts have nudged their fair value estimate for Icade slightly lower to about €21.31. This reflects a reduced price target and updated assumptions around slower revenue growth, a modestly softer profit margin, a higher discount rate and the view that asset disposals and potential special dividends may take longer to materialise.ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares
Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares
Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook
Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing
Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook
Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing
Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook
Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance
Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares
Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.ICAD: Office Risk Repricing Will Shape Margins And Share Performance
Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares
Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength
Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.A Look At Icade's (EPA:ICAD) Share Price Returns
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Aufschlüsselung der Einnahmen und Ausgaben
Wie Icade Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 25 | 1,337 | -123 | 327 | 0 |
| 30 Sep 25 | 1,338 | -155 | 331 | 0 |
| 30 Jun 25 | 1,339 | -187 | 334 | 0 |
| 31 Mar 25 | 1,376 | -231 | 335 | 0 |
| 31 Dec 24 | 1,412 | -275 | 336 | 0 |
| 30 Sep 24 | 1,468 | -614 | 339 | 0 |
| 30 Jun 24 | 1,523 | -953 | 343 | 0 |
| 31 Mar 24 | 1,524 | -1,121 | 355 | 0 |
| 31 Dec 23 | 1,525 | -1,289 | 367 | 0 |
| 30 Sep 23 | 1,494 | -1,116 | 370 | 0 |
| 30 Jun 23 | 1,464 | -944 | 372 | 0 |
| 31 Mar 23 | 1,467 | -657 | 367 | 0 |
| 31 Dec 22 | 1,469 | -370 | 361 | 0 |
| 30 Sep 22 | 1,496 | -61 | 415 | 0 |
| 30 Jun 22 | 1,524 | 249 | 468 | 0 |
| 31 Mar 22 | 1,586 | 324 | 425 | 0 |
| 31 Dec 21 | 1,648 | 399 | 382 | 0 |
| 30 Jun 21 | 1,640 | 280 | 228 | 0 |
| 31 Mar 21 | 1,534 | 178 | 225 | 0 |
| 31 Dec 20 | 1,429 | 76 | 222 | 0 |
| 30 Jun 20 | 1,458 | 259 | 224 | 0 |
| 31 Mar 20 | 1,485 | 278 | 221 | 0 |
| 31 Dec 19 | 1,512 | 298 | 218 | 0 |
| 30 Sep 19 | 1,587 | 235 | 215 | 0 |
| 30 Jun 19 | 1,662 | 173 | 212 | 0 |
| 31 Mar 19 | 1,717 | 165 | 220 | 0 |
| 31 Dec 18 | 1,773 | 156 | 229 | 0 |
| 30 Sep 18 | 1,714 | 137 | 229 | 0 |
| 30 Jun 18 | 1,655 | 118 | 230 | 0 |
| 31 Mar 18 | 1,642 | 142 | 227 | 0 |
| 31 Dec 17 | 1,629 | 165 | 224 | 0 |
| 30 Jun 17 | 1,596 | 106 | 219 | 0 |
| 31 Mar 17 | 1,542 | 75 | 212 | 0 |
| 31 Dec 16 | 1,487 | 45 | 205 | 0 |
| 30 Jun 16 | 1,391 | -101 | 204 | 0 |
| 31 Mar 16 | 1,411 | -144 | 205 | 0 |
| 31 Dec 15 | 1,431 | -187 | 206 | 0 |
| 30 Jun 15 | 1,649 | 82 | 194 | 0 |
Qualität der Erträge: ICAD ist derzeit unrentabel.
Wachsende Gewinnspanne: ICAD ist derzeit unrentabel.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: ICAD ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 31.4% pro Jahr zugenommen.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von ICAD verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: ICAD ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche REITs (2.7%) erschwert.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: ICAD hat eine negative Eigenkapitalrendite (-3.23%), da es derzeit unrentabel ist.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/23 01:25 |
| Aktienkurs zum Tagesende | 2026/06/23 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Icade wird von 18 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Celine Huynh | Barclays |
| Paul May | Barclays |
| Aaron Guy | Barclays |